Alzheimer's, Novo Nordisk and Ozempic

Ozempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Ozempic and Wegovy, the two brand names under which the company sells the GLP-1 drug semaglutide, are already blockbusters.
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in diabetes patients.
Novo’s Ozempic Linked to Reduced Alzheimer’s Diagnoses
Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.
Ozempic, Wegovy Might Help Lower Alzheimer's Risk in People With Diabetes
By Dennis Thompson HealthDay Reporter THURSDAY, Oct. 24, 2024 (HealthDay News) -- Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.
Ozempic linked to lower Alzheimer’s risk in people with Type 2 diabetes
Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.
Ozempic may significantly lower the risk of Alzheimer’s disease — here’s how
Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.
Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study
In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.
Novo Nordisk Lashes Out at Wegovy Copycats. What it Means for Hims & Hers.
The Danish drugmaker asked the agency to put semaglutide, the active ingredient in Wegovy and Ozempic, on a list of drugs ...
Pharmacists “desperation” by Novo Nordisk over semaglutide copycat block
Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports
Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, ...
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
Lilly to launch Mounjaro in rival Novo Nordisk's home country: report
Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.
Becker's Hospital Review22h
Novo Nordisk to FDA: Ozempic, Wegovy too complex to be copied
Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct.
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded ...